site logo

JPM22: M&A anxiety, Roche's comeback plan and Vir's omicron moment

Pharma execs fielded questions about their dealmaking intentions on the conference's second day, while Roche outlined plans to compete in cancer immunotherapy.

Danielle Ternes / BioPharma Dive